288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431).
Saved in:
| Title: | 288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431). |
|---|---|
| Authors: | Goyal, L.1 (AUTHOR), Al-Rajabi, R.2 (AUTHOR), Sahin, I.3 (AUTHOR), Subbiah, V.4 (AUTHOR), Vogel, A.5 (AUTHOR), Yarchoan, M.6 (AUTHOR), Pierpont, S.7 (AUTHOR), Huang, X.8 (AUTHOR), Burn, T.9 (AUTHOR), Lihou, C.10 (AUTHOR), Goluboff, E.10 (AUTHOR), Zalutskaya, A.10 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS318-S318. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.716 |
